Advertisement

Octreotide Injection

[16 March 2015]

Products Affected - Description

Octreotide injection, Caraco
50 mcg/mL, 1 mL ampule (NDC 62756-0348-44)
100 mcg/mL, 1 mL ampule (NDC 62756-0349-44)
500 mcg/mL, 1 mL ampule (NDC 62756-0351-44)
200 mcg/mL, 5 mL vial (NDC 62756-0350-40)
1000 mcg/mL, 5 mL vial (NDC 62756-0352-40)
 
Octreotide injection, Teva
50 mcg/mL, 1 mL vial (NDC 00703-3301-04)
100 mcg/mL, 1 mL vial (NDC 00703-3311-04)
500 mcg/mL, 1 mL vial (NDC 00703-3321-04)
200 mcg/mL, 5 mL vial (NDC 00703-3333-01)
1000 mcg/mL, 5 mL vial (NDC 00703-3343-01)
 
Octreotide injection, Wockhardt
100 mcg/mL, 1 mL vial (NDC 64679-0633-02)
500 mcg/mL, 1 mL vial (NDC 64679-0635-02)
200 mcg/mL, 5 mL vial (NDC 64679-0634-01)
1000 mcg/mL, 5 mL vial (NDC 64679-0632-01)

Reason for the Shortage

  • Caraco cannot provide a reason for the shortage.
  • Fresenius Kabi (formerly APP) reports that the shortage was due to increased demand for the product.
  • Sandoz discontinued octreotide injection in 2nd quarter 2013.
  • Sagent had octreotide on shortage due to increased demand for the product.
  • Teva has octreotide on shortage due to manufacturing delays.
  • West-Ward Pharmaceuticals’ parent company, Hikma Pharmaceuticals, acquired octreotide injection from Bedford in July 2014. West-Ward is not actively marketing octreotide injection except available 1000 mcg/mL, 5 mL vial.
  • Wockhardt has octreotide on back order due to an import ban.
  • Sandostatin LAR presentations from Novartis are not affected by this shortage

Available Products

Octreotide injection, Fresenius Kabi
50 mcg/mL, 1 mL vial (NDC 63323-0365-01)
100 mcg/mL, 1 mL vial (NDC 63323-0376-01)
200 mcg/mL, 5 mL vial (NDC 63323-0378-05)
500 mcg/mL, 1 mL vial (NDC 63323-0377-01)
1000 mcg/mL, 5 mL vial (NDC 63323-0379-05)

Octreotide injection, Mylan Institutional
50 mcg/mL, 1 mL syringe (NDC 67457-0239-01)
100 mcg/mL, 1 mL syringe (NDC 67457-0245-01)
500 mcg/mL, 1 mL syringe (NDC 67457-0246-01)
 
Octreotide injection, Sagent
50 mcg/mL, 1 mL vial (NDC 25021-0451-01)
100 mcg/mL, 1 mL vial (NDC 25021-0452-01)
500 mcg/mL, 1 mL vial (NDC 25021-0453-01)
200 mcg/mL, 5 mL vial (NDC 25021-0454-05)
1000 mcg/mL, 5 mL vial (NDC 25021-0455-05)
 
Sandostatin, Novartis
50 mcg/mL, 1 mL ampule (NDC 00078-0180-01)
100 mcg/mL, 1 mL ampule (NDC 00078-0181-01)
500 mcg/mL, 1 mL ampule (NDC 00078-0182-01)
200 mcg/mL, 5 mL vial (NDC 00078-0183-25)
1000 mcg/mL, 5 mL vial (NDC 00078-0184-25)

Estimated Resupply Dates

  • Fresenius Kabi, Mylan Institutional, Sagent, and Novartis have been supplying product.
  • Caraco has all octreotide presentations on long term back order and the company cannot estimate a release date.
  • Teva has all octreotide presentations on long-term back order and the company cannot estimate a release date.
  • West-Ward has octreotide injection 1,000 mcg/mL 5 mL vials on long-term back order and the company cannot estimate a release date.
  • Wockhardt has all octreotide presentations on long-term back order and the company cannot estimate a release date for these products.

Related Shortages

Updated

March 16, February 18, January 15, 2015; December 22, November 17, October 13, September 5 and 11, August 13, July 22, June 2, 12, and 19, May 7, 8, 22, and 30, April 10 and 25, March 3, 6, and 27, February 10 and 14, January 31, 2014; November 1, October 25, August 28, July 11, May 24, April 11 and 16, February 27, 2013; December 17, October 11, August 22, July 19, June 1, April 5, March 23, February 14 and 27, January 4, 2012; December 16, November 3, 9, and 23, October 18, September 6, 14, and 20, August 17, July 21, June 6, 2011, University of Utah, Drug Information Service. Copyright 2015, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement